XDx (Brisbane, CA) a commercial-stage molecular diagnostics company focused on noninvasive gene expression tests for the monitoring of immune-mediated conditions, closed a $14.4M Series G financing. Participants include Bristol Myers Squibb (NYSE: BMY), Burrill Venture Capital, DAG Ventures, Integral Capital Partners, Integral Capital Partners, Kleiner Perkins Caulfield & Byers, New Leaf Venture Partners and TPG Biotechnology.